Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone for Multiple Myeloma Patients Previously Treated with Daratumumab

Inclusion Criteria

• Diagnosed with multiple myeloma.
• Cancer has returned or not responded after at least one previous treatment, including daratumumab.
• Must have received at least 8 doses of daratumumab in the past, with a break of at least 3 months between treatments.
• Measurable disease based on specific medical tests.
• Women who can become pregnant must have a negative pregnancy test and agree to use two forms of birth control.
• General health status must be good, with a performance score of 0, 1, or 2.
• Able to take aspirin daily.
• Life expectancy of more than 3 months.
• Willing to sign informed consent.
• Meet specific blood count and organ function requirements.
• Must be registered in the POMALYST REMS program and comply with its requirements.

Exclusion Criteria

• Previous treatment with non-daratumumab anti-CD38 antibodies or pomalidomide, unless a good response was achieved.
• Severe heart problems or recent heart attack.
• Severe lung disease.
• Planned high-dose chemotherapy or stem cell transplant soon after starting treatment.
• Pregnant or breastfeeding women.
• Not fully recovered from previous chemotherapy.
• Recent major surgery or radiation therapy.
• Recent use of certain medications or supplements.
• Positive for HIV, hepatitis B, or hepatitis C.
• Serious medical or psychiatric conditions that could interfere with the study.
• Allergies to study medications.
• Recent diagnosis or treatment for another cancer, unless fully treated.
• Severe nerve damage or pain.
• Participation in another clinical trial within the last 30 days.
• Recent history of blood clots.